PeptidePedia The community reference

Contributions of EndpointEnid

User contributions·34 logged edits·page 1 of 1

Contributions by EndpointEnid, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 8,477 edits includes activity predating the current log.

  1. 17:30, 16 Jul 2026 (diff | hist) Underfilling 4,882 ±0 British spelling per PP:MOS
  2. 13:40, 25 Jun 2026 (diff | hist) Talk:CagriSema 611 +127 /* The under-titration question */ reply
  3. 14:33, 19 Jun 2026 (diff | hist) Talk:Trial data comparison 1,244 +242 /* Cross-trial tabulation and the estimand problem */ reply
  4. 02:38, 16 Jun 2026 (diff | hist) SELECT trial 5,171 ±0 fix a broken wikilink
  5. 22:10, 13 Jun 2026 (diff | hist) Residual solvent 5,085 ±0 add the equilibration time to the gradient description
  6. 00:53, 2 May 2026 (diff | hist) Intention-to-treat analysis 4,963 ±0 state the non-inferiority margin, since the design was non-inferiority
  7. 13:55, 21 Apr 2026 (diff | hist) Talk:STEP trial programme 748 +185 /* Estimands */ reply
  8. 10:40, 21 Apr 2026 (diff | hist) Talk:Survodutide 400 +180 /* Histological endpoints caveat */ new section
  9. 14:05, 16 Apr 2026 (diff | hist) Talk:SURPASS trial programme 748 +104 /* Active-comparator CVOT */ reply
  10. 04:44, 17 Mar 2026 (diff | hist) LEADER trial 4,799 ±0 add the trial registration identifier
  11. 17:14, 14 Mar 2026 (diff | hist) Xi'an Mokemei Biotechnology 15,421 ±0 m add the note that self-published material is usable only for what it states about itself
  12. 13:00, 9 Mar 2026 (diff | hist) Incretin effect 7,358 ±0 m add see also to the sister hormone
  13. 09:40, 9 Mar 2026 (diff | hist) Talk:Placebo-adjusted effect 400 +201 /* Placebo response is only one component */ new section
  14. 13:20, 17 Feb 2026 (diff | hist) Talk:SURMOUNT trial programme 611 +100 /* Curve had not plateaued */ reply
  15. 21:09, 12 Nov 2025 (diff | hist) Survodutide 5,445 ±0 expand §Status and material sold under the name
  16. 09:11, 2 Nov 2025 (diff | hist) Placebo-adjusted effect 4,805 ±0 m expand §How figures are misreported
  17. 23:44, 29 Oct 2025 (diff | hist) Prior authorisation 4,216 ±0 m rm the specific plan recommendation; out of scope
  18. 05:09, 28 Oct 2025 (diff | hist) STEP trial programme 5,534 ±0 cite the trial publication rather than the sponsor press release
  19. 05:40, 30 Sep 2025 (diff | hist) STEP trial programme 5,534 ±0 add category for the trial programme
  20. 06:20, 7 Sep 2025 (diff | hist) SELECT trial 5,171 ±0 state the analysis population: intention-to-treat or per-protocol
  21. 14:42, 28 Jun 2025 (diff | hist) SUSTAIN trial programme 4,728 ±0 m convert a hard-coded date to the house format
  22. 00:16, 12 Apr 2025 (diff | hist) FLOW trial 3,481 +25 give the absolute risk difference alongside the relative one
  23. 13:52, 23 Feb 2025 (diff | hist) Intention-to-treat analysis 3,795 ±0 give the primary endpoint as pre-specified, not as reported
  24. 20:32, 9 Feb 2025 (diff | hist) SURPASS trial programme 3,958 ±0 add the trial registration identifier
  25. 23:21, 1 Jan 2025 (diff | hist) HOMA-IR 3,178 +681 add the cross-link to the organ-function article
  26. 00:43, 19 Nov 2024 (diff | hist) Triple agonist 2,546 ±0 rm the equipotency claim — the cited paper does not make it
  27. 22:20, 16 Nov 2024 (diff | hist) Third-party testing 4,926 +481 state the date range the submitted set covers
  28. 18:54, 6 Oct 2024 (diff | hist) GLP-1 receptor agonist 6,120 +584 correct the molar mass — source gives the free-base figure, we had the salt
  29. 19:23, 29 Aug 2024 (diff | hist) Janoshik Analytical 2,844 +317 add category for certificates of analysis
  30. 00:41, 29 Aug 2024 (diff | hist) SURPASS trial programme 1,993 ±0 label the extension study as an extension study in the table
  31. 20:33, 14 Aug 2024 (diff | hist) SUSTAIN trial programme 2,571 +625 add the missing-data handling method
  32. 16:16, 21 Jul 2024 (diff | hist) Glucagon-like peptide-1 3,812 +807 state that the enzyme inhibitor class works by raising endogenous levels
  33. 17:49, 6 Jul 2024 (diff | hist) Reference standard 1,189 +1,189 N new article: analytical method, expansion welcome
  34. 09:00, 28 Jun 2024 (diff | hist) STEP trial programme 1,299 +1,299 N start article; endpoints and registration only